Unparalleled knowledge and experience
We are committed to designing, managing, and delivering clinical trials that are cost-effective and provide robust evidence for treatments for the most common illnesses affecting the world today. We have decades of experience in medical research, academia and corporate management which allows us to expertly support our partners’ pipelines, accelerating the adoption of novel treatments into routine clinical practice.
Our leadership team
The Leadership Team at Protas guide and support staff across the organisation to deliver the strategic objectives of the organisation. They bring with them a wealth of scientific, clinical and industry knowledge and patient focus to realise Protas’s ambitions.
Chief Executive Officer
Sir Martin Landray is CEO of Protas, Professor of Medicine and Epidemiology at Oxford Population Health and a consultant hospital physician. He has over 20 years’ experience of leading large, randomized trials and is a joint lead of the RECOVERY trial of treatments for COVID-19. He works closely with regulators, industry, academia, patient groups and government organizations to improve all aspects of clinical trials.
Chief Operating Officer
Dr Abby Taylor is COO and is responsible for the efficient establishment and operations of Protas. Abby was the Associate Director of Strategy and Data Insights for the Wellcome Trust where she spent almost a decade leading the development and delivery of many of Wellcome’s major strategic initiatives and its international expansion. Abby has a PhD in Biochemistry.
Chief Clinical Operations Officer
Dr Tim Peakman is Chief Clinical Operations Officer at Protas and is responsible for the efficient establishment and operation of trials. Before joining Protas he worked at University of Leeds as Chief Operating Officer and for 14 years at UK Biobank as Deputy Chief Executive helping to establish and run this study involving 500,000 participants.
Chief Finance Officer
Richard Eales is Chief Finance Officer at Protas and is responsible for oversight of all financial matters. Richard is also Interim Chief Finance Officer at the Wellcome Trust and a member of the Audit Committee of Diamond Light Source, the UK’s national synchrotron science facility.
Richard Haynes is Chief Scientist of Protas, Professor of Renal Medicine & Clinical Trials at Oxford Population Health and a consultant kidney doctor in the NHS. He has worked on and led large, randomized trials for over 15 years in cardiovascular, kidney and infectious diseases and has a keen interest in ensuring that all areas of health benefit from streamlined trials.
Chief Information Officer
Stefan Blixen-Finecke is the CIO and is responsible for the efficient establishment and operation of Protas information technology services, including the Unified Clinical Trials Management Platform. Before joining Protas, Stefan was the Chief Technology Officer at the European Medicines Agency where he led the development of strategic platforms underpinning medicines regulation in Europe. He has also held technology leadership roles at the Financial Conduct Authority and Telenor Denmark.
Our board members
The Board of Directors work to achieve the aims of the organisation. Members bring broad expertise from across academic, clinical, corporate and industry backgrounds.
The Board act as company directors and have overall responsibility for the direction and management of Protas.
Lord Prior of Brampton
David Prior was Chair of NHS England from November 2018 until March 2022. Educated at Cambridge University and a qualified barrister, he has held senior positions within the industrial and banking sectors. He has served as Parliamentary Under Secretary of State in the Department of Health and the Department of Business, Energy & Industrial Strategy. In October 2017 he became Chair of University College London Hospitals before being appointed as Chair of NHS England.
Professor Sir Rory Collins, FRS FMedSci FRCP
Rory Collins is an epidemiologist and clinical trialist. He joined Oxford University in 1981, where he has designed and conducted large streamlined randomized trials. He became principal investigator of the UK Biobank study in 2005, was knighted for Services to Science in 2011, established Oxford University’s Nuffield Department of Population Health in 2013, and was elected to the Royal Society in 2015.
Sir Jonathan Symonds CBE
Jonathan Symonds is Chair of GSK. A chartered accountant, he has extensive international financial, life sciences and governance experience. Previous roles include Chair of HSBC Bank, Chief Financial Officer of Novartis and Astra Zeneca, Non-Executive Chair of Proteus Digital Health and Non-Executive Director of Rubius Therapeutics. Jon is a Non-Executive Director of Genomics England Limited, Non-Executive Chair of Energy Aspects and a member of the European Round Table for Industry.
Professor Sir John Bell GBE FRS
John Bell is Regius Professor of Medicine, Oxford University and has been the government’s UK Life Sciences Champion since 2011. He chaired the Office for Strategic Coordination of Health Research until 2017 and currently chairs the Gates Global Health Advisory Board, Genomics England Ltd Scientific Advisory Board and Our Future Health board. He wrote the UK Life Sciences Industrial Strategy in 2017 and co-developed UK Life Sciences Vision in 2021.
Dr Beth Thompson MBE
Beth Thompson is a policy and advocacy professional. She has led Wellcome’s Policy team since 2017, championing better public policy for science and health. Much of Beth’s work has focused on the regulation and governance of health research and she was awarded an MBE in 2017 for work on the General Data Protection Regulation. Beth holds a PhD from the MRC Laboratory of Molecular Biology.
Esther Krofah MPP
Esther Krofah is the executive vice president of health for the Milken Institute. She has extensive experience managing efforts to unite diverse stakeholders to solve critical issues and achieve shared goals that improve patients’ lives. Esther previously served as the director of public policy at GlaxoSmithKline and held roles in the United States government and consulting to advance health reform. Esther received a BA from Duke University and a Master of Public Policy from Harvard University.
Latest from Protas
“A New National Purpose”: Protas named in report on innovation
Protas was this week named in a new report exploring how the UK should harness innovation in science and technology…
Protas signs strategic partnership with Moderna
Protas is delighted to announce a new strategic partnership with Moderna, the leading biotechnology company pioneering messenger RNA (mRNA). Moderna’s…